News

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

The WIO Summer Symposium offers attendees a chance to network, build practice management skills, and plan to reach new goals and milestones in their career.

Rationale for delving into this topic is the recent studies that have reported that active and healthy living can reduce IOP.

At the World Ophthalmology Congress in Vancouver, Canada, John D. Sheppard, MD, MMSc, FACS, presented data on perfluorohexyloctane ophthalmic solution in the treatment of dry eye. He sat down with Ophthalmology Times to discuss the topic in further detail.

European patients navigate new therapies and market change-ups

According to a study by a team of Korean researchers, published in BMC Ophthalmology, investigators conducted a retrospective study to examine the prevalence and clinical characteristics of ocular allergy in glaucoma patients using brinzolamide 1.0%/brimonidine 0.2% fixed combination (BBFC), with and without concurrent β-blocker.

The drop breaks up degraded protein complexes which cause lens clouding

At the World Ophthalmology Congress in Vancouver, Canada, Mahnia Madan, OD, FAAO, presented a paper on the tolerability of cosmetic products on the ocular surface. She sat down with Ophthalmology Times to discuss the topic in further detail.

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

Ophthalmologists can use OCT to find the early signs of disease

Specular microscopy showed "long-term alterations" in corneal cells

According to the company, the priority review voucher would be issued upon approval of OPGx-LCA5.

According to the company, the pre-clinical safety and efficacy studies of its product have yielded positive results in 3 internationally recognized labs in India, Singapore and the United States.

Pearls for implanting the port delivery device with ranibizumab.

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA).

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.

The team conducted a cross-sectional study from December 2016 to March 2024 in patients with acute infectious conjunctivitis

During a recent Ophthalmology Times Case-Based Roundtable discussion, Albert S. Khouri, MD, shared his pearls in proactive glaucoma management.

With many benefits, AI technology does have the potential to change the way practices work in the coming years, but it may require additional advancements in terms of relieving physician burnout and driving organization.

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

In a study, Australian ophthalmology and optometry researcher and Beatles fan Professor Stephen Vincent has analyzed John Lennon’s little-known, hit-and-miss use of contact lenses in the 1960s and found the Rock and Roll Hall of Famer was probably right when he theorized that his cannabis use helped them stay in place.

EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.